A Study of LY3537021 in Healthy Participants

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Safety and Tolerability of LY3537021 When Combined With GLP-1 Receptor Agonist in Healthy Participants

The main purpose of this study is to evaluate the safety and tolerability of LY3537021 when administered in combination with glucagon-like peptide (GLP-1) receptor agonist called liraglutide in treatment-naïve healthy participants. The study will include 2 parts. The study will last up to 16 and 22 weeks for part A and B, respectively which includes a screening period of 6 weeks.

Inclusion Criteria:

• Participants who are overtly healthy as determined through medical evaluation
• Participants with body weight at least 55 kilograms (kg) and body mass index (BMI) of 23.0 to 40.0 kilograms per meter squared (kg/m²)
• Males, or females who are not of childbearing potential.
• Capable of giving signed informed consent form
• Have blood pressure of less than 150/90 millimeters of mercury (mm Hg) and pulse rate of less than 100 beats per minute (bpm) (supine)

Exclusion Criteria:

• Have a significant history of current disorders capable of significantly altering the absorption, metabolism or elimination of drugs
• History of malignancy within 5 years prior to screening
• Have evidence of significant active psychiatric disorder(s)
• Have undergone any form of bariatric surgery
• Have an abnormality in the 12-lead electrocardiogram (ECG)
• Are females who are lactating